Moderna Announces First Participant Dosed in Phase 2 Study of Omicron-Specific Bivalent Booster Candidate

Moderna Announces First Participant Dosed in Phase 2 Study of Omicron-Specific Bivalent Booster Candidate

Source: 
Yahoo/Accesswire
snippet: 

Moderna's Omicron-specific bivalent booster candidate (mRNA-1273.214) combines Moderna's Omicron-specific booster candidate (mRNA-1273.529) and the Moderna COVID-19 vaccine (mRNA-1273)

Moderna expects to enroll approximately 375 participants in the U.S.